Sylvester Stallone TRT: What He Said About Testosterone Replacement Therapy

What Sylvester Stallone Has Said About TRT

Stallone has discussed testosterone therapy across multiple media appearances over two decades, making him one of the most prominent public figures to speak candidly about hormone replacement in men.

The 2008 Australian Customs Incident

The public record on Stallone and TRT is not based on rumor. In February 2007, Australian customs officials seized 48 vials of Jintropin (human growth hormone) and testosterone from his luggage in Sydney. He pleaded guilty to importing restricted substances and paid a fine of AUD 10,600. Shortly after, he told the Sunday Telegraph: "Everyone over 40 years old should be taking [human growth hormone]." He followed that statement by describing testosterone as equally important to his regimen, framing both as tools for physical maintenance rather than performance enhancement in a competitive sport setting.

Later Interviews and Podcast Appearances

In a 2022 appearance on a widely circulated podcast, Stallone stated he had been working with a physician to manage his testosterone levels for years. He described the goal as keeping his levels in "a good, normal range" rather than reaching supraphysiologic concentrations. That distinction matters clinically. Supraphysiologic testosterone (above approximately 1,000 ng/dL) carries greater risk for erythrocytosis, sleep apnea exacerbation, and cardiovascular strain, while replacement to the mid-normal range (450 to 700 ng/dL) is the target most endocrinologists and urologists recommend. The Endocrine Society's 2018 clinical practice guideline states that testosterone therapy should aim "to normalize serum testosterone concentrations" rather than maximize them. [1]

Inference vs. Confirmed Statement

Where the public record is incomplete, this article labels inference clearly. Stallone has not published lab values or a detailed prescription history. His statements confirm use of testosterone and HGH under physician supervision. Any claim about specific dosing or brand names beyond what he has stated directly is speculation and is not made here.

What Is TRT and Who Is a Clinical Candidate?

TRT is the medical use of exogenous testosterone to restore serum levels in men whose endogenous production has declined to a clinically symptomatic threshold. The condition is called hypogonadism or, in the context of aging, late-onset hypogonadism (LOH).

Diagnostic Criteria

The American Urological Association (AUA) 2018 guideline defines hypogonadism as a total serum testosterone below 300 ng/dL confirmed on two morning measurements, combined with symptoms such as low libido, fatigue, depressed mood, reduced muscle mass, or erectile dysfunction. [2] A single low reading is insufficient. The guideline also requires ruling out secondary causes, including pituitary adenoma, hemochromatosis, and medications that suppress the hypothalamic-pituitary-gonadal axis.

Prevalence rises sharply with age. The Massachusetts Male Aging Study found that total testosterone declines at roughly 1 to 2 percent per year after age 30, and free testosterone declines faster still. [3] By age 70, somewhere between 20 and 30 percent of men meet laboratory criteria for hypogonadism, though symptom overlap with other conditions means not all are appropriate candidates for TRT.

Symptoms That Prompt Evaluation

Clinicians typically assess for a constellation of symptoms before ordering labs:

• Persistent fatigue not explained by sleep disorders or thyroid dysfunction
• Libido decline lasting three months or more
• Loss of lean body mass despite consistent resistance training
• Morning erection frequency below two to three times per week
• Depressed mood or reduced motivation without a primary psychiatric diagnosis

No single symptom is diagnostic. The Androgen Deficiency in Aging Males (ADAM) questionnaire, validated in a 2000 study by Morley et al., uses 10 questions to screen for LOH with a sensitivity of 88 percent and specificity of 60 percent. [4]

The Clinical Evidence Behind TRT in Men Over 50

Stallone's self-reported experience, that TRT improved his training capacity and physical appearance, is consistent with controlled trial data, though effect sizes in clinical populations are more modest than the dramatic transformations sometimes described in celebrity interviews.

The Testosterone Trials (TTrials)

The most rigorously designed study of TRT in older men is the Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials funded by the National Institute on Aging. The trials enrolled 790 men aged 65 or older with total testosterone below 275 ng/dL and at least one symptom domain. At 12 months, men randomized to testosterone gel (titrated to achieve levels of 500 to 900 ng/dL) showed statistically significant improvements in sexual function, walking distance, and bone mineral density compared to placebo. [5] The sexual function trial showed a mean increase of 2.64 points on the Psychosexual Daily Questionnaire (P<0.001). The physical function trial found a 15.7-meter improvement on the six-minute walk test, though this did not meet the pre-specified threshold for clinical significance.

Lean Mass and Body Composition

A 2013 meta-analysis by Bhasin et al. (10 randomized controlled trials, N=1,083) found that TRT in hypogonadal men produced a mean increase in lean body mass of 1.63 kg and a mean reduction in fat mass of 1.22 kg compared to placebo. [6] These are real but not dramatic changes. Stallone's visible physique at age 70-plus reflects decades of resistance training, high protein intake, and professional-grade recovery protocols alongside any hormonal support, not TRT alone.

Cardiovascular Safety: The TRAVERSE Trial

Cardiovascular risk was the central concern that slowed TRT prescribing for over a decade, following a 2010 trial by Basaria et al. That was stopped early due to excess cardiac events in older men with mobility limitations. [7] The 2023 TRAVERSE trial (N=5,246) was designed specifically to resolve this question. Men aged 45 to 80 with hypogonadism and existing cardiovascular disease or elevated risk were randomized to testosterone gel 1.62% or placebo for a mean follow-up of 22 months. The primary endpoint (MACE: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) occurred in 7.0 percent of the testosterone group versus 7.3 percent in the placebo group, meeting the pre-specified non-inferiority margin. [8] The FDA reviewed the TRAVERSE data and updated testosterone prescribing information in 2024, removing the generalized cardiovascular warning for hypogonadal men at moderate risk.

Atrial fibrillation occurred more frequently in the testosterone arm (3.5% vs. 2.4%, P<0.05), a signal that physicians now document during TRT monitoring. Stallone, who has been public about cardiac health concerns in his family, would presumably receive atrial fibrillation screening as part of any responsible TRT protocol.

Erythrocytosis Risk

Hematocrit elevation is the most common dose-dependent adverse effect of TRT. The Endocrine Society guideline recommends checking hematocrit at baseline, three to six months, and then annually. [1] If hematocrit exceeds 54 percent, the guideline recommends dose reduction or temporary discontinuation. This is especially relevant for men who train at altitude or have underlying sleep apnea, both of which independently raise hematocrit.

TRT Formulations: What Older Men Typically Use

Stallone has not specified the formulation he uses, but the available options each carry distinct pharmacokinetic profiles.

Testosterone Cypionate or Enanthate (Intramuscular Injection)

Injectable testosterone esters remain the most common formulation in the United States. Testosterone cypionate (Depo-Testosterone) at 100 to 200 mg every one to two weeks produces trough-to-peak fluctuations that some patients notice as mood or energy variability. Weekly injections of 50 to 100 mg produce a flatter curve and are increasingly preferred in telehealth TRT protocols. Cost is low: a 10 mL vial of cypionate (200 mg/mL) carries a generic price under $40 at most pharmacies.

Transdermal Gels (AndroGel, Testim, Fortesta)

Topical gels deliver a daily dose through the skin, typically 50 to 100 mg applied to the shoulders or upper arms. Steady-state levels are more stable than biweekly injections. Transfer to partners or children via skin contact is a documented risk and requires hand washing and covering the application site. [9] The FDA added a black-box warning for transdermal testosterone regarding secondary exposure in 2009.

Testosterone Pellets (Testopel)

Subcutaneous pellets (150 to 450 mg depending on body weight and labs) are inserted in the upper buttock every three to six months under local anesthesia. They produce stable levels with no daily adherence burden. Removal is not possible if levels run too high, making the initial dose calculation critical.

Clomiphene Citrate (Off-Label)

Clomiphene citrate (50 mg three times weekly) stimulates endogenous LH and FSH, raising testosterone without suppressing spermatogenesis. It is not FDA-approved for hypogonadism but is widely used off-label in men who want to preserve fertility or testicular volume. A 2003 study by Guay et al. (N=36) showed mean testosterone increases from 231 ng/dL to 610 ng/dL over six months with clomiphene. [10]

How TRT Intersects With Human Growth Hormone

Stallone has mentioned both testosterone and human growth hormone (HGH) in his public statements. Clinically, these are separate prescriptions with separate indications.

FDA-Approved HGH Use in Adults

The FDA approves somatropin (synthetic HGH) for adult growth hormone deficiency (AGHD) diagnosed by IGF-1 levels and stimulation testing. [11] It is not approved for anti-aging or body composition improvement in healthy adults. Prescribing HGH to a non-deficient adult for performance or appearance purposes is off-label and carries federal risk under the Human Growth Hormone Act of 1990, which made non-medical distribution a felony.

The Overlap in Older Men

Some older men have both low testosterone and low IGF-1. In those cases, combined testosterone and HGH therapy may be prescribed by endocrinologists who document deficiency in both axes. A 2002 trial by Giannoulis et al. (N=80) found that combined GH and testosterone therapy produced greater lean mass gains and fat loss than either hormone alone in older hypogonadal men, though adverse effects including fluid retention and insulin resistance were also additive. [12]

The clinical standard in 2025 is to treat confirmed deficiency in each axis separately, with documented lab evidence and symptom criteria before initiating either therapy.

The HealthRX Age-50-Plus TRT Candidacy Checklist

Before a HealthRX physician considers TRT for a male patient aged 50 or older, the following criteria must be documented in the chart:

1. Two fasting morning total testosterone measurements below 300 ng/dL, drawn on separate days.
2. Free testosterone below 65 pg/mL (equilibrium dialysis method preferred) if total testosterone is borderline (300 to 400 ng/dL).
3. LH and FSH to distinguish primary from secondary hypogonadism.
4. Prolactin level to screen for pituitary adenoma.
5. Hematocrit below 50% at baseline.
6. PSA below 4.0 ng/mL, or documented urology clearance if above 3.0 ng/mL in a man aged 50 to 69.
7. Documented symptom burden using the ADAM questionnaire or the AMS (Aging Males' Symptoms) scale.
8. Sleep study ordered or completed if obstructive sleep apnea is suspected (snoring, Epworth score above 10, BMI above 35).
9. Baseline lipid panel, HbA1c, and liver function tests.
10. Informed consent discussion including the TRAVERSE cardiovascular data, erythrocytosis risk, and testicular atrophy from LH suppression.

Men who meet all ten criteria are candidates for a TRT trial of six months, with labs at weeks 6 to 8 and at month six before continuing.

Monitoring a TRT Protocol: What Responsible Care Looks Like

Starting TRT without a monitoring plan is the most common failure mode in direct-to-consumer hormone clinics. The Endocrine Society 2018 guideline specifies monitoring at three to six months and then annually. [1]

Lab Monitoring Schedule

At each follow-up visit, clinicians should check:

• Total and free testosterone (mid-cycle for injections, two to four hours post-application for gels)
• Hematocrit and hemoglobin
• PSA (annually after age 55, or every six months if baseline was above 1.5 ng/mL)
• Lipid panel annually

Symptom and Physical Exam Monitoring

Testicular volume decreases predictably with exogenous testosterone due to LH suppression. Men who want to preserve fertility should discuss human chorionic gonadotropin (hCG) co-administration, which maintains intratesticular testosterone and testicular size. A 2005 study by Coviello et al. Showed that hCG at 250 IU every other day fully maintained intratesticular testosterone in men on exogenous testosterone. [13]

Blood pressure and heart rate should be checked at every visit. The atrial fibrillation signal from TRAVERSE makes rhythm assessment reasonable in men over 60 who report palpitations.

What Physicians Say About Celebrity TRT Disclosures

Public figures discussing TRT openly can reduce the stigma that keeps symptomatic men from seeking evaluation. The downside is that celebrity use can create unrealistic expectations.

Dr. Shalender Bhasin, director of the Research Program in Men's Health at Brigham and Women's Hospital and lead investigator on the TTrials, has written: "Testosterone therapy in older men with low testosterone can improve sexual function, bone density, and walking capacity, but the effects on muscle strength and physical function are more modest than widely perceived." [5] That measured framing differs from the significant narrative often attached to celebrity TRT stories.

The practical takeaway: TRT can meaningfully improve quality of life in men with confirmed hypogonadism. It does not replicate the physique of a 76-year-old action star who has trained professionally since his 30s.